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Background: Cystic fibrosis (CF) is produced by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene (CFTR) gene.
Methods: One hundred twenty eight patients with CF were analysed for mutations in the CFTR gene in order to establish the frequency of CF
mutations in the Romanian population. The chief methods of analysis were polymerase chain reaction (PCR) of DNA extracted from blood and
electrophoresis of PCR products.
Results: The frequency of F508del in CF chromosomes from Romania is approximately 56.3%. Other frequent mutations noted are: G542X
(3.9%), W1282X (2.3%), and CFTRdele2,3(21 kb)(1.6%); the remaining mutations have frequencies below 1%.
Conclusions:We consider that the frequency of F508del in CF patients from Romania is higher than in previous reports, reaching 56.3%, probably
owing to more rigorous selection of patients for genetic testing, allowing improved calculation of mutation frequencies.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Mutations; Romania1. Introduction
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recessive genetic disease in Caucasian populations, is caused by⁎ Corresponding authors. Frenţescu is to be contacted at Department of Cell
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1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.03.004mutations in the CFTR gene, situated on the long arm of
chromosome 7 [1–3]. Defects of the CFTR protein, a cAMP-
dependent chloride channel, produce the clinical features of the
disease. The most frequent CFTR gene mutation worldwide
is a 3 base-pair deletion which results in the deletion of a
phenylalanine residue at codon 508 of the CFTR protein; this
mutation, F508del, accounts for 66% of CF chromosomes
worldwide [4,5].
The first study [6] of mutations in children with CF from
Romania was performed on a small number of patients and was
focused on the F508del mutation, for which a low frequency
was reported. These data were also included in the reviews on
the worldwide distribution of CFTR mutations [4,5].d by Elsevier B.V. All rights reserved.
Table 1
PCR primers and references for the analysis of 13 common mutations in the
CFTR gene
Mutation Name of primers Restriction
enzyme
Reference
R334W 7F MspI [10]
R347P 7R Hin6I
R117H 4A Hin6I [11]
621+1GNT 4B HincII
N1303K N1303F DdeI [12]
N1303R
W1282X W1182F MnlI [13]
W1282R [14]
G551D 11i5 HincII [15]
R553X 11i3 Sau3A
G542X 11ex3’ MvaI [11]
G542X
F508del CF2 [3]
I507del CF3 [16]
1677delTA C16B [17]
C16D [18]
[19]
CFTRdele2,3(21 kb) CFTRdel2,3F [20]
CFTRdel2,3R [13]
Control primers for exon 3:
3i-5
3i-3
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common and rare mutations in the CFTR gene of the largest
cohort of Romanian patients, comprising 128 patients with
confirmed CF, and their relatives, which represent the majority
of patients included in the National CF Registry.
2. Materials and methods
2.1. Patients
Venous EDTA anti-coagulated blood samples were taken
from patients and their relatives (parents and siblings). The
subjects were recruited at pediatric hospitals from Baia-Mare,
Braşov, Bucharest, Cluj-Napoca, Iaşi, Oradea, and Timişoara.
Samples were taken at the place of consultation and were sent
by mail to our laboratory.
After careful evaluation of every case, following the rec-
ommendations of the European experts for quality improvement
in genetic testing for CF [7], we included in this study 128
patients which meet the diagnosis criteria to warrant DNA
analysis, and we excluded other 77 patients because the clinical
data and/or sweat test values were not available or were not
indicative for cystic fibrosis.
2.2. DNA extraction
DNA was extracted in the Department of Cell and Molecu-
lar Biology (DCMB) of the ‘Iuliu Haţieganu’ University of
Medicine and Pharmacy Cluj-Napoca, Romania, using the
phenol-chloroform method [8], the rapid non-enzymatic method
[9] or with the Wizard® kit (Promega GmbH, Mannheim,
Germany), from 3–10 ml blood. Absorbance was measured at
260, 280 and 330 nm with a VSU-2 spectrophotometer (Karl
Zeiss, Jena, Germany); the A260/A280 ratio and the DNA
concentration were calculated. The DNA concentration was
adjusted to allow 200 ng to be used for PCR.
2.3. PCR and electrophoresis methods
Each sample was consecutively analyzed for one or more
mutations, in different laboratories and with different strategies
until two mutations were identified or the available techniques
were finished. The first patient was tested in the Laboratory of
Genetics of The ‘Henri Mondor' Hospital, Créteil, France, for
mutations situated in all exons. Nine patients were tested for 13
mutations [F508del, 1677delTA, I507del, R117H, R553X, 621+
1GNT, R334W, R347P, G55D, G542X, W1282X, N1303K,
CFTR dele2,3(21 kb)] in the Department of Human Genomics,
Institute for Molecular Biology and Genetics, National Acade-
my of Science, Kiev, Ukraine (Table 1). One sample was
analyzed in DCMB for F508del mutation. The unresolved
samples (with one or nomutations identified) were analyzed for
other common mutations included in the commercial kits
Elucigene CF20 (Orchid, Cellmark Diagnostics, Abingdon,
Oxfordshire, UK) and Linear Array CF Gold (RocheMolecular
Diagnostics, USA), in the Molecular Genetics Laboratory of
the Royal Manchester Children's Hospital (Manchester, UK)(RMCH). In the next step the remaining samples without two
identified mutations were analysed for rare mutations in more
than three-quarters of the coding sequence of the gene at
RMCH, covering all the regions where the disease-causing
mutations usually appear.
The following 117 samples were analyzed in DCMB, for a
variable number of common mutations between 3 and 26,
starting with F508del, I507del and 1677delTA, and continuing
with the commercial kits CF-3 (G542X, W1282X and
N1303K), CF-8 [F508del, I507del, 1677delTA, CFTRdele2,3
(21 kb), 2143delT, 2184insA, 394delTT, 3821delT], both pro-
duced by the Research Center for Medical Genetics, Moscow,
Russia, and Elucigene CF20. Three unresolved samples (with
one or no mutations identified) were analyzed for other com-
mon mutations included in the commercial kit Elucigene CF29
(Orchid, Cellmark Diagnostics) at RMCH. Other 17 unresolved
samples were analyzed with the commercial kits INNO-LiPA
CFTR12 and CFTR17+Tn (Innogenetics, Ghent, Belgium) in
the Center for Human Genetics from Leuven (Belgium). In the
next step the remaining samples without two identified mu-
tations were analysed for rare mutations at RMCH like the
previous samples.
PCR was performed in different thermal cyclers. The specific
DNA fragment for each mutation was amplified by PCR using
standard protocols. After PCR, the presence of PCR product was
checked by electrophoresis in a 1.8–2% agarose gel, when
necessary. The F508del, I507del, and 1677delTA mutations were
detected by heteroduplex analysis (HA) or with the CF-8 kit, both
using polyacrylamide gel electrophoresis. For CFTRdele2,3
(21 kb), the analysis of PCR products was performed by agarose
gel electrophoresis [20], or the CF-8 kit was used. For other
Table 2
Distribution of CFTR gene mutations in the group of 128 patients with CF
Mutation Number of
chromosomes
Percent of chromosomes
(128 patients,
256 chromosomes)
Cumulative
frequency
F508del 144 56.3% 56.3%
G542X 10 3.9% 60.2%
W1282X 6 2.3% 62.5%
CFTRdele2,3(21 kb) 4 1.6% 64.1%
621+1GNT 2 0.8% 64.8%
N1303K 2 0.8% 65.6%
2183AANG 2 0.8% 66.4%
R1070Q 2 0.8% 67.2%
457TATNG 1 0.4% 67.6%
R117H 1 0.4% 68.0%
R334W 1 0.4% 68.4%
R735K 1 0.4% 68.8%
R785X 1 0.4% 69.1%
E831X 1 0.4% 69.5%
3849+10 kb(CNT) 1 0.4% 69.9%
R1162X 1 0.4% 70.3%
3272−26ANG 1 0.4% 70.7%
1677delTA 1 0.4% 71.1%
1717−2ANG 1 0.4% 71.5%
E585X 1 0.4% 71.9%
2789+5GNA 1 0.4% 72.3%
Unknown 71 27.7% 100.0%
Total 256 100.0%
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enzyme digestions of PCR products were performed, followed by
the analysis of restriction products by agarose gel electrophoresis
(Table 1); alternatively, the kits from Belgium and UKmentioned
above, were used for selected samples, especially for hetero-
zygous patients with F508del and an unknown mutation. For
detection of sequence changes (mutations, polymorphisms) in
negative samples for common mutations, PCR followed by theFig. 1. Identification of R735K mutaSingle Strand Conformation Polymorphism (SSCP) analysis was
used in combination with HA for several exons (4, 5, 6, 7, 10, 13,
14a, 17a, 19, 20, and 21), and multiplex PCR followed by
Denaturing Gradient Gel Electrophoresis (DGGE) for different
exons, in groups of 3:multiplexA,B, C and E [21, 22].With these
methods the coding sequence of the gene was screened in 68% of
the patients with unknown mutations. For samples with sequence
changes detected by SSCP+HA and DGGE, direct sequencing
of the exons that showed an abnormal pattern of bands was
performed by the classic Sanger method or by fluorescent se-
quencing [23].
For confirmation of the E831X mutation, detected by SSCP
analysis, the same PCR products were digested with the
restriction enzyme Hpy188III, and separated by agarose gel
electrophoresis.
For all analyses we used the PCR primers described for the
amplification of the CFTR gene [13, 22].
3. Results
The mutation frequencies were calculated for 128 patients
(256 chromosomes) with CF. The results are given in Table 2.
The R735K mutation, previously undescribed, was analyzed
by fluorescent sequencing (Fig. 1).
The CFTRdele2,3(21 kb) mutation was seen for the first time
in CF chromosomes from Romania.
We identified one patient apparently harbouring three muta-
tions in the CFTR gene; the genotype is F508del/F508del/
R117H. Fresh blood samples from the patient and parents are
necessary for confirmation of this result.
The distribution of genotypes and ethnicity in this group of
patients is given in Table 3.
From the total number of 128 patients with CF we detected
both mutations in the majority of them (77), one mutation in 30tion by fluorescent sequencing.
Table 3
Distribution of genotypes in CF patients from Romania (n=128; 256
chromosomes)
Genotype Number Ethnicity
F508del/F508del 46 Romanian 42
Hungarian 3
Gypsy 1
F508del/x 25 Romanian 23
Hungarian 1
Turkish–Romanian 1
F508del/G542X 8 Romanian
F508del/CFTRdele2,3(21 kb) 4 Romanian 3
Hungarian 1
F508del/W1282X 3 Romanian
F508del/F508del/R117H 1 Romanian
F508del/R334W 1 Romanian
F508del/621+1GNT 1 Romanian
F508del/N1303K 1 Romanian
F508del/2183AANG 1 Romanian
F508del/3849+10 kb(CNT) 1 Romanian
F508del/3272−26ANG 1 Romanian
F508del/R1162X 1 Romanian
F508del/R785X 1 Romanian
F508del/1717−2ANG 1 Romanian
F508del/2789+5GNA 1 Romanian
G542X/G542X 1 Romanian
W1282X/W1282X 1 Romanian
N1303K/457TATNG 1 Romanian
621+1GNT/2183AANG 1 Romanian
W1282X/x 1 Romanian
R1070Q/E585X 1 Romanian
R1070Q/x 1 Romanian
E831X/x 1 Gypsy
R735K/x 1 Romanian
1677delTA/x 1 Romanian
x/x 21 Romanian 18
Hungarian 2
Gypsy 1
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detection rate obtained by this collaborative work was 72.3%.
Four common polymorphisms were detected (5T allele with
4% frequency, 2694T/G, 3030G/A, and R75Q), and a specific
polymorphism in three Romanian patients in exon 13 was
noted, namely 2377C/T. Regarding the frequency of 5T allele,
we detected one case from 27 patients that were analyzed with
the kits that detect this polymorphism (Linear Array CF Gold
and CFTR17+Tn).
In the cohort of 142 relatives tested, we found 61 chro-
mosomes with F508del, 6 with W1282X, 4 with G542X, and
one of each with N1303K, CFTRdele2,3(21 kb), and 1717−
2ANG.
4. Discussion
This is the first comprehensive and accurate analysis of the
CFTR mutations in CF patients from Romania. This study
started when the first diagnostic samples were received from
clinicians who suspected that their patients had CF. Sweat
testing using modern equipment has only recently become
possible, but alternative methods like the measurement of nasal
potential difference and rectal chloride transport (intestinalcurrent measurement) are also in use. We propose that in earlier
studies of Romanian CF patients, the study cohort included
individuals whose diagnosis was not correctly ascertained,
leading to reduced frequencies of F508del: 37.5% (Pop et al.,
personal communication, 1994), and 25% [6]. In 1997 the
relative frequency of F508del in Romania was estimated at 42%
[4]. Recent data indicated a frequency of F508del in Romanian
CF patients between 33.3% (M. Schwarz, personal commu-
nication) and 36.6% [5]. We believe that the frequency of
F508del in Romania was underestimated because of problems
with the clinical diagnosis, but progress in this area is evident
and in parallel with improvements of clinical diagnosis and the
performance of sweat testing, the frequency of mutations and
especially of F508del increases.
In our previous preliminary studies, performed on a smaller
number of patients, but with a careful selection of samples, a
frequency of 61.2% of the F508del mutation was reported [24].
In the present study, the number of patients is significant for an
accurate estimation of mutation frequencies; it seems that in
Romania, like in the majority of European countries, the
F508del mutation has the highest frequency (56.3%). In the last
5 years we have identified more rare mutations and as the
increasing experience of clinicians has enabled improved se-
lection of patients, we can now present a considerably more
comprehensive panel of CFTR mutations in patients from
Romania. The most frequent five mutations in Europe are:
F508del 66.8%; G542X 2.6%; N1303K 1.6%; G551D 1.5%
and W1282X 1% [5]. From the five most frequent mutations in
Europe, only G551D was not noted in this study; this mutation
is of Celtic origin. With some exceptions like 457TATNG and
E831X, the rest of mutations are generally common in Europe.
The CFTRdele2,3(21 kb) mutation is of Slavic origin and is
frequent in Central and Eastern Europe [20]; we have identified
this mutation for the first time in Romanian population. The
mutation 457TATNG was described in a Slovenian CF patient
[25]. This mutation, together with CFTRdele2,3(21 kb) were
found in populations from regions close to Romania, and its
appearance in the Romanian population is not surprising.
We found a new mutation, R735K, that was reported to the
Cystic Fibrosis Genetic Analysis Consortium. It is possible that
the mutation R735K changes the activity of the ion channel
through modifications of one of the consensus sites for Protein
Kinase A. The mutation may produce a moderate change and
we can predict that the ion channel has a reduced activity. This
can explain the mild respiratory disease of this patient. How-
ever, until now, a second mutation has not been identified, and it
is difficult to determine the pathological nature of the R735K
mutation.
The polymorphism 2377C/T has no known consequence.
The leucine at codon 749 remains unchanged, so it is likely to
be a silent polymorphism. This base change has not been
previously reported and is therefore likely to be specific to, or
originating in the Romanian population.
It is known that the profile of mutations in the CFTR gene in
different countries and areas reflects the heterogeneity of their
inhabitants [26]. Regarding the mutations detected, we noted
a moderate heterogeneity with 21 mutations detected, the
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G551D), and a similarity with the mutations detected in Italy,
France and Spain [5]. Frequent mutations in the Mediterranean
region, as well as mutations of Jewish and Slavic origin, were
noted in Romania. These data may give an insight to the origin
of the Romanian people, from the admixture of local inhabitants
(Dacians) and Roman colonists established in the first three
centuries B.C. with migrant Slavic populations coming in the
subsequent centuries and being assimilated by the Romanian
people.
It is likely that CF is still under-ascertained in Romania,
because there is a very small number of a patient in comparison
with other European countries with approximately the same
population, suggesting that there are still difficulties with the
clinical diagnosis. It is important to select for DNA testing only
those patients with a clear diagnosis or strong suspicion. Be-
cause this condition is realized in our study, a possible re-
maining reason for the comparative low detection rate obtained
is the relative ethnic heterogeneity of Romanian population,
when compared with other European populations. There re-
main, however, a considerable number of unknown mutations
in our CF patients; future testing of rare mutations in the
Romanian CF population will improve the detection rate.
5. Conclusions
In the group of 128 Romanian patients with CF tested for
CFTR mutations, the F508del mutation was the most frequent.
We consider that the frequency of F508del mutation in CF
patients from Romania is higher than in previous reports,
reaching 56%, probably because of a better selection of patients
for genetic testing and for calculations ofmutations' frequencies.
We also report here the frequencies for other common CFTR
mutations in this population.
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